S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
The Elites Are Waging War on Elon Musk — Here's Why… (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
The Elites Are Waging War on Elon Musk — Here's Why… (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
The Elites Are Waging War on Elon Musk — Here's Why… (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
The Elites Are Waging War on Elon Musk — Here's Why… (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift

Nektar Therapeutics (NKTR) Earnings Date, Estimates & Call Transcripts

$0.69
+0.03 (+4.55%)
(As of 02/21/2024 ET)
Skip Charts & View Estimated and Actual Earnings Data

NKTR Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

NKTR Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Nektar Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20242($0.20)($0.15)($0.18) 
Q2 20242($0.18)($0.13)($0.16) 
Q3 20242($0.18)($0.13)($0.16) 
Q4 20242($0.31)($0.13)($0.22) 
FY 20248($0.87)($0.54)($0.71) 
Q1 20251($0.19)($0.19)($0.19) 
Q2 20251($0.18)($0.18)($0.18) 
Q3 20251($0.18)($0.18)($0.18) 
Q4 20251($0.27)($0.27)($0.27) 
FY 20254($0.82)($0.82) ($0.82)

NKTR Earnings Date and Information

Nektar Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 27th, 2024 based off prior year's report dates.

Nektar Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
2/27/2024
Estimated)
------- 
11/7/2023Q3 2023($0.18)($0.19)($0.01)($0.14)$20.68 million$24.14 million
8/8/2023Q2 2023($0.30)($0.27)+$0.03($0.27)$20.94 million$20.50 million    
5/9/2023Q1 2023($0.26)($0.25)+$0.01$0.23$20.60 million$21.59 million
2/28/2023Q4 2022($0.43)($0.32)+$0.11($0.32)$22.21 million$22.02 million
11/3/2022Q3 2022($0.47)($0.24)+$0.23($0.17)$23.31 million$23.63 million
8/4/2022Q2 2022($1.01)($0.85)+$0.16($0.85)$22.75 million$21.59 million    
5/5/2022Q1 2022($0.72)($0.49)+$0.23($0.49)$24.89 million$24.82 million
2/28/2022Q4 2021($0.81)($0.79)+$0.02($0.79)$25.33 million$25.00 million    
11/4/2021Q3 2021($0.80)($0.70)+$0.10($0.70)$27.94 million$24.92 million    
8/5/2021Q2 2021($0.72)($0.69)+$0.03($0.69)$26.42 million$28.33 million      
5/6/2021Q1 2021($0.72)($0.68)+$0.04($0.68)$26.15 million$23.60 million  
2/25/2021Q4 2020($0.68)($0.65)+$0.03($0.65)$19.64 million$23.46 million  












Nektar Therapeutics Earnings - Frequently Asked Questions

When is Nektar Therapeutics's earnings date?

Nektar Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 27th, 2024 based off last year's report dates. Learn more on NKTR's earnings history.

How much revenue does Nektar Therapeutics generate each year?

Nektar Therapeutics (NASDAQ:NKTR) has a recorded annual revenue of $92.06 million.

How much profit does Nektar Therapeutics generate each year?

Nektar Therapeutics (NASDAQ:NKTR) has a recorded net income of -$368.20 million. NKTR has generated -$1.56 earnings per share over the last four quarters.

What is Nektar Therapeutics's EPS forecast for next year?

Nektar Therapeutics's earnings are expected to decrease from ($0.83) per share to ($0.87) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:NKTR) was last updated on 2/22/2024 by MarketBeat.com Staff